INDP (Indaptus Therapeutics) EBIT : $-15.37 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Indaptus Therapeutics EBIT?

Indaptus Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-3.14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-15.37 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Indaptus Therapeutics's annualized ROC % for the quarter that ended in Sep. 2024 was -818.50%. Indaptus Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -10,696.17%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -316.27%.

Indaptus Therapeutics EBIT Historical Data

The historical data trend for Indaptus Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indaptus Therapeutics EBIT Chart

Indaptus Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-3.60

-7.73

-14.91

-16.38

Indaptus Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial													-4.25	-4.18	-3.94	-4.11	-3.14

Competitive Comparison of Indaptus Therapeutics's EBIT

For the Biotechnology subindustry, Indaptus Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indaptus Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's EV-to-EBIT falls into.

Indaptus Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.37 Mil.

Indaptus Therapeutics (NAS:INDP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Indaptus Therapeutics's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-12.568 * ( 1 - 0% )	/	( (1.417	+	1.654)	/ 2 )
=	-12.568	/	1.5355
=	-818.50 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.122	-	1.145	-	( 7.302	-	max(0, 1.928	-	7.488	+	7.302	))
=	1.417

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.24	-	1.189	-	( 7.381	-	max(0, 2.232	-	7.629	+	7.381	))
=	1.654

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Indaptus Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-12.568	/	( ( (0.129 + max(-1.639, 0))	+	(0.106 + max(-1.88, 0)) )	/	2 )
=	-12.568	/	( ( 0.129	+	0.106 )	/	2 )
=	-12.568	/	0.1175
=	-10,696.17 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.186)	-	(1.145	+	0	+	0.68)
=	-1.639

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.248)	-	(1.189	+	0	+	0.939)
=	-1.88

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Indaptus Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-15.374	/	4.861
	=	-316.27 %

Indaptus Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Indaptus Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Indaptus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Columbus Circle, 15th Floor, New York, NY, USA, 10019

Website

https://www.indaptusrx.com

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Executives

Glen R. Anderson	10 percent owner	3274 ROSS ROAD, PALO ALTO CA 94303
Roger J. Waltzman	officer: Chief Medical Officer	C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Robert Martell	director	4 MAGUIRE ROAD, LEXINGTON MA 02421
Boyan Vesselinov Litchev	officer: Chief Medical Officer	13357 RUSSET LEAF LN., SAN DIEGO CA 92129
Jeffrey A Meckler	director, officer: Chief Executive Officer	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Walt Addison Linscott	officer: Chief Business Officer	1860 MONTREAL ROAD, TUCKER GA 30084
Michael James Newman	director, 10 percent owner, officer: Chief Scientific Officer	C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Mark John Gilbert	director	13731 NORTHWOOD RD., NW, SEATTLE WA 98177
Brian O'callaghan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Hoonmo Lee	director, 10 percent owner	C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes	director	231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah	director	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Nir Sassi	officer: Chief Financial Officer	3 ELUL STREET, APT. 6, MODIIN L3 7176397